Skip to main content

INVEGA HAFYERA

NDC 50458-611 · Janssen Pharmaceuticals, Inc

Generic namepaliperidone palmitate
Dosage formINJECTION, SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
Active ingredient(s)PALIPERIDONE PALMITATE
Strength1092 mg/3.5mL
Pharmacologic classAtypical Antipsychotic [EPC]
Marketing categoryNDA

Packages

50458-611-01 — 1 SYRINGE in 1 CARTON (50458-611-01) / 3.5 mL in 1 SYRINGE

Billed under HCPCS

J2427 — Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg Medicare Part B payment limit (ASP + 6%): $13.26

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

50458-560 — paliperidone palmitate, 50458-561 — paliperidone palmitate, 50458-562 — paliperidone palmitate, 50458-563 — paliperidone palmitate, 50458-564 — paliperidone palmitate, 50458-606 — paliperidone palmitate, 50458-607 — paliperidone palmitate, 50458-608 — paliperidone palmitate, 50458-609 — paliperidone palmitate, 50458-612 — paliperidone palmitate, 72526-105 — paliperidone palmitate, 72526-106 — paliperidone palmitate, 72526-107 — paliperidone palmitate, 72526-108 — paliperidone palmitate, 72526-109 — paliperidone palmitate, 72526-110 — paliperidone palmitate

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels